Bilcare GCS Expands Capabilities

Bilcare Global Clinical Supplies has enhanced its ability to develop formulation dosage forms for preclinical and early-phase drugs with the addition of fluid bed granulation technology and the In-Cap capsule system.
   
The fluid bed granulation technology extends Bilcare’s solid-dosage formulation capabilities. The system is equipped with Wurster coating inserts, enabling the delivery of specialized, high-precision coating processes for granules and non-pareils for the creation of sustained- and controlled-release tablet and capsule formulations.
   
The In-Cap capsule system for preclinical and early-stage development is capable of filling several thousand capsules per hour in multiple permutations. This equipment adds development and clinical manufacturing capabilities for various formulation types, including powders, pellets, tablets and liquids.
   
According to Vincent Santa Maria, president of Bilcare GCS, Americas, the addition of new technology is part of the company’s capital investment program in its U.S. facilities. “With these upgrades, Bilcare GCS can now quickly produce a wider variety of drug dosage forms with high product quality at or above industry standards,” he said. “These investments in R&D services further prove our commitment to being a full-service partner to our global customers.”